Hedgehog/Gli Signaling: SMO Activation, Primary Cilia, and Transcriptional Control by Gli Proteins

# Hedgehog/Gli Signaling: Smoothened Activation, Primary Cilia, and Transcriptional Programs

Research Use Only (RUO) — Not for Human or Animal Therapeutic Use

The Hedgehog (Hh) signaling pathway is a morphogenetic signal transduction system that governs cell fate, tissue patterning, and stem cell maintenance across virtually all vertebrate organ systems. Named for the Drosophila segment polarity gene whose loss produces a spiny larval cuticle, the pathway has been conserved from arthropods to mammals with remarkable fidelity. In vertebrates, canonical Hedgehog signaling is uniquely dependent on primary cilia — solitary microtubule-based organelles that project from the surface of most quiescent cells and serve as dedicated signaling compartments for the Hedgehog pathway. The central logic involves two membrane receptors (PTCH1 and SMO) operating in an epistatic relay: PTCH1 constitutively suppresses SMO until Hedgehog ligand binding relieves this suppression, allowing SMO to activate Gli transcription factors that drive target gene expression. Pharmacological inhibition of SMO (vismodegib, sonidegib) provided the first molecularly targeted therapy for basal cell carcinoma, validating the pathway as a tractable therapeutic target. This review synthesizes the structural and mechanistic basis of Hedgehog signal transduction, the unique role of primary cilia, and the research tools enabling pathway dissection.

Hedgehog Ligands: Structure, Lipid Modification, and Gradient Formation

Three Mammalian Hedgehog Ligands

Mammals express three Hedgehog ligands: Sonic Hedgehog (SHH), Desert Hedgehog (DHH), and Indian Hedgehog (IHH). All three share the same domain architecture — a C-terminal autoprocessing/cholesterol transferase domain (Hint domain) and an N-terminal signaling domain (HhN). During biosynthesis, the Hint domain undergoes intramolecular autocleavage, covalently attaching a cholesterol moiety to the C-terminus of HhN. Simultaneously, the acyltransferase Hhat (Hedgehog acyltransferase, also called Skinny hedgehog) palmitoylates HhN at the N-terminal cysteine (Cys24 in SHH). The mature, dually lipidated HhN — with C-terminal cholesterol and N-terminal palmitoyl — is the active signaling molecule.

Both lipid modifications are essential for Hedgehog signaling activity. The cholesterol modification anchors HhN to the outer membrane leaflet and drives formation of multimeric Hedgehog complexes (via the cholesterol-cholesterol interface). The palmitoyl group contacts the PTCH1 sterol-sensing domain (SSD) directly and is required for high-affinity PTCH1 binding. Disruption of either lipid modification produces signaling-incompetent or short-range Hedgehog molecules.

Dispatched and SCUBE2: Lipoprotein-Associated Hedgehog Release

Despite their membrane anchoring, Hedgehog proteins must be released from producing cells and form long-range morphogen gradients in target tissues. This apparent paradox is resolved by dedicated release machinery: Dispatched-1 (DISP1), a 12-pass transmembrane protein structurally related to NPC1 (Niemann-Pick type C1 lipid transporter), promotes Hedgehog release from the cell surface. SCUBE2 (signal peptide, CUB domain, EGF-like 2) acts as a co-factor that extracts lipidated Hedgehog from the membrane into soluble lipoprotein particles or exosomes for long-range transport. Mutations in DISP1 cause holoprosencephaly-like phenotypes consistent with absent SHH gradient formation.

PTCH1 and SMO: Epistatic Receptor Relay

PTCH1: A Sterol Pump That Keeps SMO Silent

Patched-1 (PTCH1) is a 12-pass transmembrane protein with two extracellular loops that form the Hedgehog-binding site and a sterol-sensing domain (SSD) — a structural module shared with HMG-CoA reductase, NPC1, and SCAP — that mediates lipid transport activity. The molecular mechanism by which PTCH1 suppresses SMO remained elusive for decades but has been substantially clarified by structural studies (Qi et al., 2018; Gong et al., 2018): PTCH1 functions as a lipid transporter that depletes oxysterols (oxidized cholesterol derivatives) from the inner membrane leaflet of cilia. SMO requires oxysterol binding to its extracellular cysteine-rich domain (CRD) for activation — PTCH1-mediated oxysterol depletion around SMO keeps SMO in an inactive conformation. This model explains why PTCH1 acts catalytically on SMO (one PTCH1 molecule can suppress multiple SMO molecules) and why cholesterol-related lipid transport modulators affect Hedgehog signaling.

PTCH1 is itself a direct Hedgehog transcriptional target — as cells are exposed to Hedgehog, PTCH1 expression increases, providing negative feedback that raises the threshold for signaling in responding cells. PTCH1 loss-of-function mutations (LOF) are the most common genetic event in basal cell carcinoma (~75% of BCCs), gorlin syndrome (basal cell nevus syndrome), and medulloblastoma, causing constitutive SMO activity independent of Hedgehog ligand.

SMO: A 7-TM GPCR-Like Signal Transducer

Smoothened (SMO) is a class Frizzled (class F) GPCR with seven transmembrane helices, an extracellular cysteine-rich domain (CRD), and a long intracellular C-terminal tail. Despite its GPCR topology, SMO couples to downstream effectors through mechanisms distinct from classical Gα-protein coupling. SMO undergoes a dramatic conformational transition upon activation:

In the inactive state, the SMO CRD sits atop the 7-TM bundle, maintained in an inward-facing conformation. Oxysterol binding to the CRD and a second binding site within the 7-TM bundle stabilizes SMO in an active, outward-open conformation. Crystal and cryo-EM structures of SMO in inactive (bound to antagonist SANT-1 or cyclopamine) vs. active (bound to agonist SAG or 20(S)-OHC) states revealed the structural basis for ligand-dependent SMO activation and provided the molecular template for SMO inhibitor design (Wang et al., 2014; Byrne et al., 2016).

Activated SMO accumulates in primary cilia — a ciliary enrichment driven by the GPCR kinase 2 (GRK2) and β-arrestin machinery that normally desensitizes classical GPCRs. Ciliary SMO phosphorylation and β-arrestin recruitment in cilia is required, rather than inhibitory, for downstream Gli activation in the Hedgehog context.

Primary Cilia: The Hedgehog Signaling Organelle

Ciliogenesis and IFT: The Hedgehog Highway

Primary cilia are built from a mother centriole (basal body) that nucleates an axoneme of nine doublet microtubules (9+0 arrangement, lacking the central pair found in motile cilia). The axoneme extends into a solitary finger-like protrusion from the cell surface, enclosed by a ciliary membrane biochemically distinct from the plasma membrane. Cargo transport along the axoneme is driven by intraflagellar transport (IFT) complexes: anterograde transport (base to tip) by kinesin-2 (KIF3A/KIF3B/KAP), retrograde transport (tip to base) by dynein-2 (DYNC2H1/DYNC2LI1), and cargo loaded in IFT-A (retrograde cargo adaptor) and IFT-B (anterograde cargo adaptor) complexes.

Multiple human ciliopathies — Bardet-Biedl syndrome (BBS, BBSome complex), Joubert syndrome (CPLANE proteins, RPGRIP1L, NPHP1), Meckel-Gruber syndrome (TMEM67, RPGRIP1L) — show Hedgehog signaling defects as core pathological features, demonstrating that primary cilia integrity is essential for Hedgehog signal transduction in vivo.

Compartmentalization of Hedgehog Signaling Components in Cilia

The primary cilium provides a restricted membrane and cytoskeletal compartment where Hedgehog signaling components are dynamically segregated:

In Hh-off state: PTCH1 localizes to the ciliary membrane; SMO is excluded from cilia (maintained in intracellular vesicles); the Gli-SUFU complex (Suppressor of Fused/Gli) localizes to the ciliary tip, where Gli2/3 undergo limited proteolytic processing by PKA/CK1/GSK3β phosphorylation → β-TrCP-mediated ubiquitination → proteasomal partial cleavage, generating repressor forms (Gli3R primarily, some Gli2R).

In Hh-on state: Hedgehog ligand binding to PTCH1 triggers PTCH1 exit from cilia → SMO moves into cilia (ciliary accumulation within 30–60 min of Hedgehog stimulation) → SMO activates the GPCR kinase/β-arrestin machinery → Gli2/3 full-length activators accumulate at ciliary tip → Gli activators dissociate from SUFU → Gli activators translocate to nucleus.

The ciliary tip is the critical compartment for Gli activation: SUFU tethers Gli at the ciliary tip in the absence of Hedgehog, and SMO-driven SUFU dissociation at the ciliary tip is the activation switch. Mutations preventing ciliary tip localization of Gli2/3 or SUFU dissociation at the tip abolish Hedgehog-driven transcriptional activation.

Gli Transcription Factor Family

Gli1, Gli2, Gli3: Zinc-Finger Transcription Factors

The three mammalian Gli proteins (Gli1, Gli2, Gli3) are zinc-finger transcription factors that bind the consensus GACCACCCA sequence (Gli binding site, GBS) in target gene promoters. Each Gli harbors five C2H2-type zinc fingers that contact a ~9-bp consensus. Beyond the DNA-binding domain, Gli proteins contain:

• •N-terminal repressor domain: Present in Gli2 and Gli3 (but divergent in Gli1); mediates transcriptional repression when Gli2R/Gli3R are the predominant forms
• •SUFU interaction domain: Approximately 100–200 aa N-terminal to the zinc fingers; SUFU binding sequesters Gli in the cytoplasm/ciliary tip
• •C-terminal transcriptional activation domain (TAD): Present in all three; recruits CBP/p300, MED12, TFIID
• •Processing determinant domain: C-terminal to the zinc fingers; contains the PKA/CK1/GSK3β phosphorylation sites that drive partial proteolytic processing into Gli repressor forms

Gli1: The most potent activator; no repressor domain; not processed into a repressor form. Gli1 is itself a direct Hedgehog transcriptional target — its expression is entirely Hedgehog-dependent, making it the most reliable reporter for active Hedgehog signaling. Gli1 amplifies the transcriptional program initiated by Gli2.

Gli2: The primary Hedgehog activator in most contexts. Gli2 full-length (Gli2A) is the dominant activator generated by Hedgehog signaling; Gli2 repressor (Gli2R) is generated at low efficiency by partial proteolytic processing and has limited repressive activity in most tissues.

Gli3: The primary repressor in most contexts. Gli3 full-length (Gli3A) can act as a weak activator, but Gli3R (generated efficiently by partial proteolysis in Hh-off conditions) is the dominant form and a potent transcriptional repressor at GBS sites. The Gli3A/Gli3R ratio is a major determinant of the Hedgehog transcriptional output in limb and brain development.

Gli Processing: PKA, CK1, GSK3β, and Partial Proteolysis

Gli2/3 undergo phosphorylation-dependent partial proteolytic processing to generate repressor forms. The processing cascade:

1. PKA (cAMP-dependent protein kinase A) phosphorylates the processing determinant domain at Ser849, Ser863, Ser895, Ser902 (Gli3 numbering) — sites that are constitutively phosphorylated by the basally active PKA in Hh-off cells.

2. CK1α/ε phosphorylates at additional sites primed by PKA (hierarchical phosphorylation — CK1 requires PKA priming).

3. GSK3β phosphorylates at further C-terminal sites after CK1 priming.

4. The multiply-phosphorylated Gli2/3 recruits β-TrCP via a pSGXXpS degron (analogous to β-catenin processing), and the SCF-β-TrCP E3 ubiquitin ligase ubiquitinates Gli2/3 C-terminally.

5. Partial proteasomal degradation of the C-terminal transcriptional activation domain generates Gli3R (~83 kDa, truncated at residue ~530 of full-length ~190 kDa Gli3).

Hedgehog/SMO signaling inhibits PKA-driven Gli processing by reducing the efficiency of Gli2/3 phosphorylation, tilting the balance toward full-length Gli activator forms. The molecular mechanism connecting SMO to PKA inhibition involves a SMO-dependent reduction in ciliary adenylyl cyclase activity (reducing cAMP) and possibly direct Gi-protein coupling by SMO.

Hedgehog Target Gene Programs

Direct Gli Target Genes

Gli transcription factors directly activate a network of target genes controlling cell proliferation, survival, and fate:

Feedback regulators: PTCH1 (negative feedback, raises Hh threshold), PTCH2, HHIP (Hedgehog-interacting protein, secreted Hedgehog antagonist), GLI1 (positive feedback amplifier), SUFU (negative feedback)

Proliferative programs: CCND1 (cyclin D1), CCND2 (cyclin D2), BCL2, MYCN (N-Myc in neural contexts), CDC25B

Developmental programs: FOXA2 (floorplate fate in neural tube), NKX2.2, NKX6.1 (ventral neural progenitor identity), OLIG2 (oligodendrocyte/motor neuron progenitor), RUNX2 (bone development, IHH target in growth plate), SOX9 (chondrogenesis, IHH target)

Angiogenic and stromal programs: VEGF (Gli1/2 direct target in some contexts), Angiopoietin-1, PDGFR-β (Gli target in stromal cells of tumor microenvironment)

Tissue-Specific Hedgehog Programs

Neural tube dorsal-ventral patterning: SHH from the notochord and ventral floorplate establishes a ventral-high, dorsal-low concentration gradient that specifies five distinct progenitor domains (p3: Nkx2.2, pMN: Olig2/Nkx6.1, p2: Irx3/Pax6, p1: Dbx2, p0: Evx1) through threshold responses to Gli3R:Gli2A ratios. The combinatorial interpretation of a single morphogen gradient into five cell fates is the classical demonstration of Hedgehog concentration-dependent cell fate specification.

Limb development: SHH from the zone of polarizing activity (ZPA) in the posterior limb bud specifies digit identity. Gli3R establishes an anterior repressor gradient; SHH from the ZPA activates Gli2A and suppresses Gli3 processing posteriorly. Digit identity is specified by the ratio of anterior Gli3R to posterior Gli activator.

Hair follicle cycling: SHH from the dermal papilla signals to epithelial matrix cells during anagen (growth) phase of the hair follicle cycle, driving proliferation via Gli1/CCND1. Blocking Hedgehog (by PTCH1 loss) in hair follicle stem cells is sufficient to induce BCC-like tumors.

Cerebellar granule neuron development: SHH from Purkinje cells signals to granule cell precursors (GCPs) in the external granular layer of the cerebellum, driving CCND1/N-Myc-dependent GCP expansion. Constitutive Hedgehog activation in GCPs (by PTCH1 loss or Smoothened gain-of-function) generates medulloblastoma — a pediatric cerebellar tumor responsive to SMO inhibitors (vismodegib).

Research Tools

Experimental Protocols

Protocol 1: Hedgehog Pathway Activation — SAG-Stimulated Gli1 Induction

Objective: Quantify Smoothened-dependent Gli1 target gene induction using SAG (Smoothened agonist) as a PTCH1-bypass activator.

Materials: NIH-3T3 fibroblasts (highly Hh-responsive); SAG (10 µM stock in DMSO); recombinant SHH N-terminus (carrier-free); vismodegib; cyclopamine; Gli1 antibody; PTCH1 antibody (negative feedback marker); HHIP antibody.

Protocol:

1. Seed NIH-3T3 at 2 × 10⁵/well in 6-well plates; grow 48 h to confluence (quiescence enhances ciliation).

2. Serum-reduce to 0.5% FBS 16–24 h (promotes ciliogenesis).

3. Stimulate: vehicle, SAG (100 nM–3 µM), recombinant SHH N-domain (0.3–3 µg/mL), cyclopamine (5 µM) as SMO antagonist control, vismodegib (1 µM) + SAG (1 µM) to confirm SMO-dependence.

4. 24 h stimulation; lyse; Western blot for Gli1, PTCH1, SUFU; qRT-PCR for Gli1, Ptch1, Hhip, Gli2.

5. Quantify Gli1 protein induction vs. vehicle.

Expected: SAG (300 nM): 5–30-fold Gli1 protein induction; 10–50-fold Gli1 mRNA; PTCH1 protein and mRNA increase 3–10-fold (direct Gli target, negative feedback); HHIP mRNA increases 5–20-fold. Cyclopamine and vismodegib pre-treatment (at SMO-competitive concentrations) completely block SAG-driven Gli1 induction. SHH N-domain: similar pattern, typically 5–20-fold Gli1 induction at 1–3 µg/mL.

Protocol 2: SMO Ciliary Accumulation by Immunofluorescence

Objective: Directly visualize Hedgehog-driven SMO ciliary enrichment and PTCH1 ciliary exit as a readout of pathway activation.

Materials: NIH-3T3 or IMCD3 cells; anti-SMO antibody (Santa Cruz sc-166685 or Abcam ab38686); anti-PTCH1 antibody; anti-ARL13B antibody (ciliary marker); anti-acetylated tubulin antibody (ciliary axoneme marker); SAG (300 nM); vismodegib (1 µM); confocal microscope with structured illumination (SIM) or standard confocal.

Protocol:

1. Seed on fibronectin-coated glass coverslips; grow to confluence; serum-starve 24 h to maximize ciliation (>70% cells should be ciliated).

2. Treat: vehicle, SAG (300 nM, 60 min), vismodegib (1 µM, 30 min pretreatment then SAG 300 nM 60 min).

3. Fix 4% PFA 10 min RT; permeabilize 0.1% Triton X-100 5 min (gentle, preserve ciliary structure).

4. Block 5% BSA 1 h; dual stain: anti-SMO (rabbit, 1:200) + anti-ARL13B (mouse, 1:500) overnight 4°C.

5. Alexa 555 (SMO) + Alexa 488 (ARL13B) secondary antibodies; DAPI; mount Prolong Gold.

6. Confocal acquisition: Z-stack through cilia; project maximum intensity for SMO/ARL13B channel overlay.

7. Quantify: Score cilia as SMO-positive (SMO signal ≥2× background within ARL13B+ ciliary region) or SMO-negative in ≥50 cilia/condition.

Expected: Vehicle: <20% cilia SMO-positive (SMO excluded from cilia); PTCH1 localizes to cilia (~60–80% PTCH1-positive cilia). SAG 300 nM: >80% cilia become SMO-positive within 30–60 min; PTCH1 redistributes out of cilia. Vismodegib blocks SAG-driven ciliary SMO accumulation by >70% (vismodegib traps SMO in inactive CRD-7TM closed conformation, preventing ciliary entry).

Protocol 3: Gli Transcriptional Reporter Assay (8×Gli-BS-Luc)

Objective: Quantify Gli transcriptional activity using the standard Gli binding site-luciferase reporter system.

Materials: 8×Gli-BS-luciferase plasmid (8 tandem GACCACCCA sequences driving firefly Luc; Addgene #37,771 or equivalent); pRL-TK Renilla; NIH-3T3, C3H10T1/2, or HEK293 cells; SAG, SHH, Gli1 or Gli2 constitutively active expression vectors (for positive control); GANT61; vismodegib.

Protocol:

1. Transfect 24-well plates: 8×Gli-BS-Luc (400 ng) + pRL-TK (40 ng) ± Gli1 expression vector (100–400 ng).

2. 24 h post-transfect; serum-starve 0.5% FBS 16 h.

3. Stimulate: vehicle, SAG (0.3–3 µM), SHH N-domain (1–3 µg/mL), Gli1 expression (constitutive control) ± vismodegib (1 µM), GANT61 (10–20 µM).

4. 24 h stimulation; Dual-Luciferase assay.

5. For PTCH1-null control: transfect PTCH1 siRNA 48 h prior (should yield constitutive 8×Gli-BS-Luc activity independent of SAG).

Expected: Vehicle: minimal reporter activity. SAG (1 µM): 10–50-fold induction. SHH N-domain (3 µg/mL): 8–30-fold induction. Gli1 overexpression: 50–200-fold constitutive induction. Vismodegib blocks SAG-driven (but not Gli1 overexpression-driven) reporter activity, demonstrating SMO-dependence. GANT61 suppresses Gli1-overexpression-driven reporter, demonstrating Gli1 DNA-binding requirement.

Protocol 4: Gli3 Processing Assay — PKA-Driven Repressor Generation

Objective: Biochemically demonstrate Gli3 full-length → Gli3R processing and its modulation by Hedgehog signaling and PKA activity.

Materials: Mouse embryonic fibroblasts (MEFs) or NIH-3T3; Gli3 antibody detecting both full-length (~190 kDa) and Gli3R (~83 kDa) forms (R&D Systems AF3690 or equivalent); dibutyryl cAMP (db-cAMP, PKA activator, 1 mM); H-89 (PKA inhibitor, 10 µM); SAG (1 µM); MG132 (proteasome inhibitor, 10 µM, to accumulate processing intermediates); 6–8% SDS-PAGE required to resolve full-length vs. Gli3R.

Protocol:

1. Treat MEFs: vehicle, SAG (1 µM, 4 h), db-cAMP (1 mM, 4 h), H-89 (10 µM, 2 h pretreat then vehicle or SAG), MG132 (10 µM, 4 h, to block proteasomal processing).

2. Lyse in RIPA; run on 6–8% polyacrylamide gel (long run, ~3–4 h at 100 V for resolution of the 83/190 kDa doublet).

3. Transfer to PVDF; probe anti-Gli3 antibody; detect both bands.

4. Quantify Gli3R/Gli3FL ratio by densitometry.

Expected: Vehicle: high Gli3R/Gli3FL ratio (~2:1 or greater, reflecting constitutive processing in Hh-off state). SAG: reduces Gli3R/Gli3FL ratio (increased full-length relative to repressor, Gli processing inhibited by SMO activation). db-cAMP: increases Gli3R/Gli3FL (PKA activation → more processing). H-89 (PKA inhibitor): reduces Gli3R/Gli3FL (PKA inhibition → reduced processing, mimics partial Hh activation). MG132: accumulates both Gli3 processing intermediate and full-length (reveals processing is proteasome-dependent).

Protocol 5: Primary Cilia Quantification and Ciliation Rate by Automated Imaging

Objective: Quantify ciliation rate across multiple conditions using automated multi-channel high-content microscopy as a prerequisite for Hedgehog signaling studies.

Materials: Multiple cell lines (NIH-3T3, RPE1, IMCD3); anti-ARL13B (ciliary membrane), anti-γ-tubulin (basal body), anti-acetylated tubulin (axoneme); DAPI; serum starvation (0.5% FBS, 24–48 h); Opera Phenix or ImageXpress high-content imager.

Protocol:

1. Seed cells in 96-well plates (1,500–3,000 cells/well); grow 24 h; switch to 0.5% FBS 24 h or 48 h.

2. Fix 4% PFA; permeabilize 0.2% Triton X-100; block 5% BSA.

3. Triple-stain: ARL13B (cilia length/identity), γ-tubulin (basal body, marks ciliated cells even when cilia are short), DAPI.

4. Acquire 10–20 fields/well on high-content imager.

5. Automated analysis: (a) Segment nuclei (DAPI → cell count); (b) detect basal body spots (γ-tubulin); (c) detect elongated ARL13B structures adjacent to γ-tubulin spots; (d) calculate: % ciliated cells (basal body + ARL13B co-localization/total cells), mean cilia length (ARL13B structure length).

6. Compare: control medium vs. serum starvation 24h vs. 48h; IFT88 siRNA as cilia-negative control (should reduce % ciliation to <10%).

Expected: NIH-3T3 in 10% FBS: ~20–40% ciliated. After 24 h 0.5% FBS: ~70–85% ciliated. After 48 h: >85% ciliated. RPE1: highly ciliated even in serum (>80%). IFT88 siRNA: <10% ciliated. Quantification confirms that subsequent Hedgehog experiments (SAG stimulation, SMO localization) are performed in optimally ciliated cell populations.

Disease Contexts and Pathway Dysregulation

Basal Cell Carcinoma (BCC): PTCH1 Loss

BCC is the most common human malignancy, driven in ~75% of cases by inactivating PTCH1 mutations. The remaining cases harbor activating SMO mutations (including the W535L mutation that renders SMO constitutively active and vismodegib-resistant). Vismodegib was the first FDA-approved hedgehog pathway inhibitor, demonstrating efficacy in locally advanced and metastatic BCC. Acquired resistance to vismodegib is dominated by secondary SMO mutations (D473H, W535L, L225F) that reduce vismodegib binding affinity while maintaining constitutive SMO activity.

Gorlin Syndrome (Basal Cell Nevus Syndrome)

Gorlin syndrome is an autosomal dominant disorder caused by heterozygous germline PTCH1 loss-of-function mutations. Affected individuals develop numerous BCCs beginning in the second decade of life, medulloblastomas (particularly desmoplastic variant), calcifying odontogenic keratocysts, bifid ribs, and skeletal anomalies. The syndrome provided the first genetic evidence that PTCH1 is a tumor suppressor whose loss drives constitutive Hedgehog/SMO signaling.

Medulloblastoma: SHH Subgroup

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. The SHH subgroup (~30% of MB) is driven by constitutive Hedgehog activation through PTCH1 loss, SMO gain-of-function, SUFU loss, or GLI2 amplification. SHH-MB arises from cerebellar granule cell precursors (GCPs) whose normal Purkinje-cell-derived SHH signaling drives controlled CCND1/N-Myc-driven expansion. Vismodegib has shown activity in adult SHH-MB but limited efficacy in pediatric cases due to growth plate closure effects (on-target Hh inhibition in bone) and acquired SMO resistance.

Rhabdomyosarcoma and Pancreatic Cancer

GLI1/2 amplification or overexpression drives Hedgehog pathway activation in a subset of rhabdomyosarcomas and pancreatic cancers independently of PTCH1/SMO mutations. In pancreatic ductal adenocarcinoma, stromal Hedgehog signaling (IHH/DHH from cancer cells → GLI1+ stromal fibroblasts) creates a desmoplastic microenvironment that restricts chemotherapy delivery. Paradoxically, clinical trials of SMO inhibitors in PDAC failed, possibly because stromal Hh signaling was restraining, not promoting, tumor growth — the paracrine context determines whether Hedgehog signaling promotes or suppresses tumor progression.

Summary

Hedgehog signaling is a uniquely cilia-dependent morphogenetic pathway in vertebrates that converts positional and concentration information in developing tissues into precise Gli transcriptional programs. The epistatic PTCH1-SMO receptor relay, oxysterol-mediated SMO regulation, and cilia-compartmentalized Gli processing provide a signal transmission mechanism that achieves both ligand dose-sensing and spatial precision. The pathway's direct involvement in BCC, medulloblastoma, and developmental ciliopathies has generated one of the richest collections of research tools in developmental biology: SMO agonists (SAG, purmorphamine, 20(S)-OHC) and antagonists (vismodegib, cyclopamine, SANT-1), Gli inhibitors (GANT61, GANT58), transcriptional reporters (8×Gli-BS-Luc, Gli1-GFP knock-in mice), and ciliary imaging tools (ARL13B, IFT88 siRNA, IFT-B FRAP) collectively enable dissection of every pathway node from ligand to genome.

---

For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.

References

1. Ingham PW, McMahon AP (2001). Hedgehog signaling in animal development: paradigms and principles. Genes & Development, 15(23), 3059–3087. PMID: 11731473

3. Wang C, et al. (2014). Structure of the human smoothened receptor bound to an antitumour agent. Nature, 497(7449), 338–343. PMID: 23636324

4. Byrne EF, et al. (2016). Structural basis of Smoothened regulation by its extracellular domains. Nature, 535(7613), 517–522. PMID: 27437577

5. Rohatgi R, Milenkovic L, Scott MP (2007). Patched1 regulates hedgehog signaling at the primary cilium. Science, 317(5836), 372–376. PMID: 17641202

6. Huangfu D, et al. (2003). Hedgehog signalling in the mouse requires intraflagellar transport proteins. Nature, 426(6962), 83–87. PMID: 14603322

7. Briscoe J, Thérond PP (2013). The mechanisms of Hedgehog signalling and its roles in development and disease. Nature Reviews Molecular Cell Biology, 14(7), 416–429. PMID: 23719536

8. Rimkus TK, et al. (2016). Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers, 8(2), 22. PMID: 26901223

9. Low JA, de Sauvage FJ (2010). Clinical experience with Hedgehog pathway inhibitors. Journal of Clinical Oncology, 28(36), 5321–5326. PMID: 21041717

10. Rubin LL, de Sauvage FJ (2006). Targeting the Hedgehog pathway in cancer. Nature Reviews Drug Discovery, 5(12), 1026–1033. PMID: 17139287

11. Goetz SC, Anderson KV (2010). The primary cilium: a signalling centre during vertebrate development. Nature Reviews Genetics, 11(5), 331–344. PMID: 20395968

13. Scales SJ, de Sauvage FJ (2009). Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends in Pharmacological Sciences, 30(6), 303–312. PMID: 19443052